Encore Medical Research

Encore Medical Research specializes in conducting a wide range of clinical trials from Phase 1 through Phase 4 across more than 50 therapeutic areas. The company is recognized for its high patient retention rate (>99%) and advanced use of data analytics. It has contributed to over 2,700 clinical trials with more than 130,000 research patients participating in its network. Current active studies include those for diabetes drugs such as semaglutide and tirzepatide combinations; treatments for atopic dermatitis; pediatric insomnia; hidradenitis suppurativa; chronic kidney disease; migraine in children/adolescents; vitiligo; prurigo nodularis; and ulcerative colitis among others.